TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05956418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine
Description: Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
Study: NCT05955560

Intervention type: DEVICE
Group type: OTHER
Intervention: PureWick Male External Catheter
Description: The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.

Intervention type: DEVICE
Group type: OTHER
Intervention: PureWick Male External Catheter
Description: The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sage PrimoFit
Description: The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sage PrimoFit
Description: The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
Study: NCT03997318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMDC-USR
Description: Autologous Muscle Derived Cells for Urinary Sphincter Repair

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.
Study: NCT06399146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus App
Description: Take a photo off the patient's skin (sternum).
Study: NCT00013130

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provision of health status information to patients provider
Study: NCT05516251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Supraorbital Nerve Stimulator
Description: SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 25Mg Tab
Description: Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
Study: NCT05957276

Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
Study: NCT06107491

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative educational videos plus routine education
Description: Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative routine education
Description: Mothers receiving routine education before their children receiving congenital heart disease surgery
Study: NCT04963179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womed Leaf
Description: Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days.
Study: NCT03522155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered communication of life expectancy
Description: The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
Study: NCT04931225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
Study: NCT06293846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: What I Learned at Home
Description: What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
Study: NCT06272747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-S003
Description: IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study: NCT05724602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: 3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
Study: NCT06174441

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Investigational product 1 (CPMSM)
Description: Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Investigational product 2 (HC+)
Description: Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
Study: NCT05024565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged intravenous infusion of β-lactams Antibiotics
Description: (1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
Study: NCT05061160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Aerobic Exercise training Group
Description: Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic Exercise training Group
Description: Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down.
Study: NCT05996081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence toolkit
Description: The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
Study: NCT05168475

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Hospital stock of rituximab used as intervention; biosimilars are allowed

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Hospital stock of rituximab used as intervention; biosimilars are allowed

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Hospital stock of rituximab used as intervention; biosimilars are allowed

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: Hospital stock of infliximab is used in the trial; biosimilars are allowed

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Hospital stock of infliximab is used in the trial; biosimilars are allowed

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Hospital stock of infliximab is used in the trial; biosimilars are allowed
Study: NCT04831502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 Capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 Capsules.
Study: NCT05168475

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Hospital-supplied stock.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Hospital-supplied stock.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Hospital-supplied stock.
Study: NCT04429009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZEPHYRx Respiratory Therapy (RT) System
Description: A breath controlled video game system for respiratory therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Incentive Spirometer
Description: A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
Study: NCT05702320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the heating procedure
Description: The patients will undergo a heating procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the heating procedure
Description: The patients will undergo a heating procedure.
Study: NCT05900427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
Study: NCT06218004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with chemotherapy
Description: envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with chemotherapy
Description: envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
Study: NCT04991480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART4215
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
Study: NCT06316466

Intervention type: OTHER
Intervention: Lp(a)
Description: The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.

Intervention type: OTHER
Intervention: Lp(a)
Description: The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
Study: NCT06055426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bed bath application
Description: Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
Study: NCT04879745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyVoice:Rheum
Description: Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: Participants in this arm will be given a copy of an existing patient pamphlet
Study: NCT05740722

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamid riboside
Description: 500 mg x 2 po

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study: NCT05925894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma
Description: 60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma
Description: 60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma
Description: 60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
Study: NCT06018961

Intervention type: OTHER
Intervention: Post-operative ileus surgery
Description: Collection of ileus events, items of IFEED score and surgical complications
Study: NCT06116253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) Scan
Description: Participants will undergo a 1-hour research MRI scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m Pentetate
Description: Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
Study: NCT05920941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]JAB-21822
Description: Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
Study: NCT05471362

Intervention type: DEVICE
Intervention: Postpartum IUD
Description: Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
Study: NCT05062668

Intervention type: PROCEDURE
Intervention: cataract operation and istent
Description: a cataract operation and the placement of one or two iStent inject or inject W at the same time

Intervention type: PROCEDURE
Intervention: cataract operation only
Description: Patients have a classic postoperative treatment after cataract.
Study: NCT05147857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilapan s
Description: is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
Study: NCT05892627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PoZibio
Description: PoZibio (50 x 10\^9 CFUs/ CAPSULE)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05329740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Injection
Description: All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
Study: NCT04736459

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination
Description: The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination
Description: The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
Study: NCT05942248

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT06051773

Intervention type: OTHER
Intervention: muscle involvement
Description: evaluation of muscle involvement